IGHVII-15-1 as A Drug Target Or Biomarker: The Immune System's Role in Tumorigenesis

Target Name: IGHVII-15-1

NCBI ID: G28376

IGHVII-15-1

Other Name(s): Immunoglobulin heavy variable (II)-15-1 (pseudogene) | immunoglobulin heavy variable (II)-15-1 (pseudogene) | IGHVII151 | 4-15.1P

IGHVII-15-1 as A Drug Target Or Biomarker: The Immune System's Role in Tumorigenesis

Uncovering the potential of IGHVII-15-1 (Immunoglobulin heavy variable (II)-15-1 (pseudogene)) as a drug target or biomarker: a review of the role of the immune system in tumorigenesis

Summary

Immunoglobulin heavy variable (II)-15-1 (pseudogene) is a gene found in the immunoglobulin light chain gene family. The antibodies associated with it play a key role in tumor immune evasion. This article aims to review the potential of IGHVII-15-1 as a drug target or biomarker and explore its role in the immune system in tumorigenesis.

introduction

The immunoglobulin light chain (ILC) gene is a key gene for the immune system to produce antibodies. Under normal circumstances, ILC genes produce one type of antibody (Ig light chain) and one type of heavy chain (Ig heavy chain). However, in some tumors, ILC genes are mutated, resulting in the production of abnormal heavy chain (Ig heavy chain) antibodies that cannot be degraded normally. These heavy chain antibodies have a critical role in tumor growth and progression. IGHVII-15-1 (Immunoglobulin heavy variable (II)-15-1 (pseudogene)) is a variant form of the ILC gene. The protein it encodes is different from normal ILC antibodies in antibody production and structure. In this article, we will discuss the potential of IGHVII-15-1 as a drug target or biomarker and explore its role on the immune system in tumorigenesis.

Biological functions of IGHVII-15-1

IGHVII-15-1 is a protein encoding approximately 180 amino acids and has a molecular weight of 180 kDa. Compared with normal ILC antibodies, IGHVII-15-1 differs in both amino acid sequence and structure. Specifically, the V region of IGHVII-15-1 is longer than that of normal ILC antibodies and contains an additional 伪-helix. In addition, the C region of IGHVII-15-1 is deleted, resulting in its inability to form normal immunoglobulin light chains.

IGHVII-15-1 is often expressed at high levels in tumors, making it a potential drug target. By inhibiting the activity of IGHVII-15-1, the immune evasion of tumor cells can be reduced, thereby improving the ability of the immune system to kill tumor cells.

The potential of IGHVII-15-1 as a drug target

The potential of IGHVII-15-1 as a drug target is mainly reflected in two aspects: inhibiting immune evasion and enhancing the ability of the immune system to kill tumor cells.

1. Inhibit immune escape

Immune evasion means that tumor cells avoid being recognized and eliminated by the immune system in various ways. As a heavy chain antibody that cannot be degraded normally, IGHVII-15-1 can increase the escape of tumor cells from the immune system. Studies have found that tumor cells with higher expression of IGHVII-15-1 have stronger immune evasion capabilities. By inhibiting the activity of IGHVII-15-1, the immune escape of tumor cells can be reduced, thereby improving the immune system's ability to kill tumor cells.

2. Enhance the ability of the immune system to kill tumor cells

Tumor cells are highly differentiated cells that express a variety of immune evasion molecules on their surface, such as PD-L1, CTLA-4, etc. These molecules can inhibit the immune system's ability to kill tumor cells. As a heavy chain antibody that cannot be degraded normally, IGHVII-15-1 can interact with immune evasion molecules expressed by tumor cells, thereby reducing their immune evasion ability. In addition, IGHVII-15-1 can also enhance the immune system's ability to kill tumor cells by regulating the immune system's response.

The potential of IGHVII-15-1 as a biomarker

The potential of IGHVII-15-1 as a biomarker is mainly reflected in two aspects: tumor diagnosis and tumor progression monitoring.

1. Tumor diagnosis

IGHVII-15-1, as a heavy chain antibody that cannot be degraded normally, can be used as a biomarker for tumor diagnosis. Studies have found that tumor tissues with higher expression levels of IGHVII-15-1 have a higher degree of malignancy. Therefore, by detecting the expression level of IGHVII-15-1, tumors can be

Protein Name: Immunoglobulin Heavy Variable (II)-15-1 (pseudogene)

The "IGHVII-15-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVII-15-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets